8-K: Amgen Q2 2025 Earnings Soar on Strong Product Sales

Amgen reported robust second quarter 2025 financial results, with total revenues up 9% to $9.2 billion and GAAP EPS increasing 92% to $2.65, driven by strong product volume growth and pipeline advancements.

Summary

• Total revenues increased 9% year-over-year to $9.2 billion in the second quarter of 2025.
• Product sales grew 9% to $8.771 billion, driven by 13% volume growth, partially offset by 3% lower net selling price.
• GAAP earnings per share (EPS) increased 92% from $1.38 to $2.65.
• Non-GAAP EPS increased 21% from $4.97 to $6.02.
• GAAP operating income increased from $1.9 billion to $2.7 billion, with GAAP operating margin rising 6.6 percentage points to 30.3%.
• Non-GAAP operating income increased from $3.9 billion to $4.3 billion, with non-GAAP operating margin rising 0.7 percentage points to 48.9%.
• Free cash flow for the second quarter of 2025 was $1.9 billion, down from $2.2 billion in Q2 2024, primarily due to deferred 2024 tax payments to 2025 and higher capital expenditures.
• Fifteen products delivered at least double-digit sales growth, including Repatha (+31% to $696 million), EVENITY (+32% to $518 million), IMDELLTRA/IMDYLLTRA (+65% quarter-over-quarter to $134 million), BLINCYTO (+45% to $384 million), TEZSPIRE (+46% to $342 million), UPLIZNA (+91% to $176 million), and TAVNEOS (+55% to $110 million).
• Prolia sales decreased 4% to $1.1 billion, and Enbrel sales decreased 34% to $604 million.
• XGEVA sales decreased 5% to $532 million, with expected sales erosion in the second half of 2025 due to biosimilar competition.
• Research & Development (R&D) expenses increased 21% (GAAP) and 18% (non-GAAP), driven by investments in later-stage clinical programs, including MariTide.
• The company retired $1.4 billion of debt during the second quarter of 2025, bringing the year-to-date total to $4.3 billion.
• Cash and cash equivalents totaled $8.0 billion and debt outstanding totaled $56.2 billion as of June 30, 2025.
• The company declared a second quarter 2025 dividend of $2.38 per share, representing a 6% increase from the same period in 2024.

Sentiment

Score: 8

Explanation: Amgen delivered exceptional Q2 2025 results, significantly surpassing prior year performance in both revenue and EPS. The company's core product portfolio demonstrated robust volume growth, with 15 products achieving double-digit sales increases. Crucially, the pipeline is advancing with highly promising data, particularly for MariTide (GLP-1/GIPR) and IMDELLTRA (oncology), which have the potential to be significant future revenue drivers. The positive Phase 3 results for Bemarituzumab and Breakthrough Therapy Designation for LUMAKRAS further de-risk the pipeline. While free cash flow decreased and some products face biosimilar competition, the overall strength of the portfolio, strategic R&D investments, and confident 2025 guidance suggest sustained growth and strong long-term value creation. The 6% dividend increase also signals management's confidence.

Positives

• Total revenues increased 9% year-over-year to $9.2 billion.
• Product sales grew 9%, driven by strong 13% volume growth.
• GAAP EPS increased significantly by 92% to $2.65, and non-GAAP EPS rose 21% to $6.02.
• GAAP operating income increased from $1.9 billion to $2.7 billion, with operating margin improving by 6.6 percentage points.
• Fifteen products achieved double-digit sales growth, demonstrating broad portfolio strength.
• MariTide (GLP-1/GIPR) Phase 2 study showed promising results with up to ~20% average weight loss and no weight loss plateau by 52 weeks, along with robust HbA1c reduction.
• IMDELLTRA (tarlatamab) Phase 3 DeLLphi-304 trial reduced the risk of death by 40% and significantly extended median overall survival by more than five months in small cell lung cancer.
• Bemarituzumab Phase 3 FORTITUDE-101 clinical trial met its primary endpoint of overall survival in gastric/gastroesophageal junction cancer.
• LUMAKRAS received Breakthrough Therapy Designation from the FDA for first-line KRAS G12C-mutated metastatic colorectal cancer.
• Nplate Phase 3 RECITE study met its primary endpoint, showing more patients on Nplate had no chemotherapy dose modifications due to chemotherapy-induced thrombocytopenia.
• The company retired $1.4 billion of debt in Q2 2025, contributing to $4.3 billion year-to-date debt reduction.
• A 6% increase in the quarterly dividend to $2.38 per share was declared and paid.

Negatives

• Free cash flow decreased to $1.9 billion in Q2 2025 from $2.2 billion in Q2 2024, primarily due to deferred 2024 tax payments to 2025 and higher capital expenditures.
• Prolia sales decreased 4% year-over-year to $1.1 billion, driven by lower net selling price, with expected sales erosion in the second half of 2025 due to biosimilar competition.
• Enbrel sales decreased 34% year-over-year to $604 million, impacted by unfavorable changes to estimated sales deductions, lower net selling price, increased 340B Program mix, and the U.S. Medicare Part D redesign.
• XGEVA sales decreased 5% year-over-year to $532 million, with expected sales erosion in the second half of 2025 due to biosimilar competition.
• Established products sales decreased 5% year-over-year to $533 million, driven by lower net selling price and lower volume.

Risks

• Ability to successfully market both new and existing products domestically and internationally.
• Clinical and regulatory developments involving current and future products.
• Sales growth of recently launched products and competition from other products, including biosimilars.
• Difficulties or delays in manufacturing products and global economic conditions, including those resulting from geopolitical relations and government actions.
• Sales of products are affected by pricing pressure, political and public scrutiny, and reimbursement policies imposed by third-party payers.
• Research, testing, pricing, marketing, and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities.
• Identification of safety, side effects, or manufacturing problems with products after they are on the market.
• Impact of government investigations, litigation, and product liability claims.
• Impact of the adoption of new tax legislation or exposure to additional tax liabilities.
• Challenges to, invalidation of, or circumvention of patents and patent applications by competitors, or failure to prevail in intellectual property litigation.
• Reliance on a few key facilities for commercial manufacturing activities and dependence on third parties for a portion of manufacturing activities, which may constrain sales.
• Significant adverse effect on the supply of materials, product distribution, commercialization, and clinical trial operations due to disease outbreaks or public health threats.
• Reliance on collaborations with third parties for product candidate development and commercialization.
• Competition with other companies for marketed products and for the discovery and development of new products.
• Uncertainty that any particular product candidate or new indication for an existing product will be successful and become a commercial product.
• Reliance on sole third-party suppliers for certain raw materials, medical devices, and component parts.
• Substantial purchasing leverage of certain distributors, customers, and payers.
• Discovery of significant problems with a product similar to one of the company's products that implicate an entire class of products.
• Unsuccessful efforts to collaborate with or acquire other companies, products, or technology, or to integrate acquired operations.
• Inability to realize strategic benefits, synergies, or opportunities from the Horizon acquisition, or longer/more difficult/costlier integration than expected.
• Compromise of confidentiality, integrity, and availability of information technology systems and data due to breakdown, cyberattack, or information security breach.
• Stock price volatility affected by a number of events.
• Negative impact on business and operations from the failure, or perceived failure, of achieving sustainability objectives.
• Negative effects on business and operations from global climate change and related natural disasters.
• Global economic conditions magnifying certain risks.
• Business performance affecting or limiting the ability of the Board of Directors to declare a dividend or the ability to pay a dividend or repurchase common stock.
• Inability to access capital and credit markets on favorable terms, or at all.

Future Outlook

Amgen expects full-year 2025 total revenues in the range of $35.0 billion to $36.0 billion, GAAP EPS between $10.97 and $12.11, and non-GAAP EPS between $20.20 and $21.30. Capital expenditures are projected to be approximately $2.3 billion, with share repurchases not exceeding $500 million. The company anticipates significant pipeline advancements, including data readouts for MariTide Phase 2 studies in Q4 2025, Repatha Phase 3 in H2 2025, and the initiation of new Phase 3 studies for MariTide and Olpasiran in H2 2025/H1 2026. Regulatory decisions are expected for UPLIZNA by December 2025 and TEZSPIRE by October 2025.

Management Comments

• "We're delivering strong performance and reaching more patients with innovative medicines and biosimilars that address serious diseases. We continue to invest in science that enables longer, healthier lives and supports sustainable, long-term growth."

Industry Context

Amgen's strong second-quarter performance, particularly in revenue and EPS growth, positions it favorably within the competitive biotechnology and pharmaceutical industry. The significant investment in R&D, especially for late-stage clinical programs like MariTide (a GLP-1/GIPR agonist), reflects the industry's focus on high-growth therapeutic areas such as obesity and diabetes. The positive Phase 3 results for IMDELLTRA in small cell lung cancer and Bemarituzumab in gastric cancer highlight Amgen's continued strength in oncology, a key growth driver across the sector. While the company faces biosimilar competition for established products like Prolia and XGEVA, a common trend for originator biologics, its robust pipeline and strategic focus on innovative medicines and biosimilars indicate a proactive approach to maintaining market relevance and growth in a dynamic landscape.

Comparison to Industry Standards

• MariTide's reported weight loss of up to ~20% in people with obesity without Type 2 diabetes and ~17% with Type 2 diabetes, along with a robust HbA1c reduction of up to 2.2%, positions it competitively against leading GLP-1 agonists such as Novo Nordisk's Ozempic/Wegovy (semaglutide) and Eli Lilly's Mounjaro/Zepbound (tirzepatide), which have demonstrated similar or slightly higher weight loss percentages in their respective trials (e.g., semaglutide typically around 15-17%, tirzepatide around 20-22%). The observation of 'no weight loss plateau by 52 weeks' for MariTide could be a key differentiator, suggesting potential for sustained or greater long-term efficacy compared to some current market leaders.
• IMDELLTRA's Phase 3 data showing a 40% reduction in the risk of death and an extension of median overall survival by more than five months in small cell lung cancer (SCLC) patients who progressed on platinum-based chemotherapy represents a clinically meaningful improvement in a disease with limited treatment options. This outcome is significant and could set a new standard of care, comparable to the impact of other novel oncology therapies that have achieved similar survival benefits in difficult-to-treat cancers.
• Bemarituzumab's statistically significant and clinically meaningful improvement in overall survival in first-line gastric or gastroesophageal junction cancer with FGFR2b overexpression aligns with the success of other targeted therapies in oncology, such as trastuzumab for HER2-positive gastric cancer, demonstrating the value of precision medicine approaches in improving patient outcomes.
• The sales erosion experienced by Prolia and XGEVA due to biosimilar competition is a standard industry trend following patent expiry, mirroring the market dynamics seen with other biologics like Humira (adalimumab) and Rituxan (rituximab), where biosimilar entry typically leads to price erosion and market share shifts for the originator product.
• The 6% increase in the quarterly dividend reflects a strong financial position and commitment to shareholder returns, a practice common among established, profitable pharmaceutical companies like Johnson & Johnson or Pfizer, which often balance R&D investment with consistent dividend growth.

Legal Proceedings

• Adjustments to non-GAAP financial measures include certain items associated with legal proceedings.
• GAAP operating expenses include litigation expenses.

Stakeholder Impact

• Shareholders are positively impacted by strong financial results, significant EPS growth, and a 6% increase in the quarterly dividend, indicating robust returns and confidence in future performance.
• Patients stand to benefit from continued investment in innovative medicines, with promising pipeline advancements in areas like obesity (MariTide), oncology (IMDELLTRA, Bemarituzumab, LUMAKRAS), and rare diseases, potentially leading to new and improved treatment options.
• Employees may experience stability and growth opportunities due to the company's strong financial performance and increased R&D investments in late-stage clinical programs.
• Customers and payers may benefit from increased competition and potentially lower prices for certain products as biosimilars for Prolia and XGEVA have launched in the U.S. market.

Next Steps

• MariTide Phase 2 chronic weight management and Type 2 Diabetes studies data readout anticipated in Q4 2025.
• Planning to initiate a Phase 3 study of MariTide for obstructive sleep apnea in H2 2025.
• Repatha VESALIUS-CV Phase 3 cardiovascular outcomes study data readout anticipated in H2 2025.
• A Phase 3 cardiovascular outcomes study for Olpasiran is expected to be initiated in H2 2025/H1 2026.
• UPLIZNA MINT Phase 3 data in generalized myasthenia gravis is under FDA review with a PDUFA date of December 14, 2025.
• TEPEZZA regulatory review is underway in multiple additional geographies following EU marketing authorization.
• FDA review of TEZSPIRE WAYPOINT Phase 3 data in chronic rhinosinusitis with nasal polyps is ongoing with a PDUFA date of October 19, 2025.
• Rocatinlimab ROCKET ASCEND and ROCKET ASTRO Phase 3 studies data readout anticipated in H2 2025.
• Planning to initiate a potentially registration-enabling Phase 2 portion of the subcutaneous blinatumomab study in H2 2025.
• Regulatory filing activities are underway for IMDELLTRA following positive Phase 3 results.
• Detailed results from Bemarituzumab FORTITUDE-101 clinical trial will be shared at a future medical meeting.
• Bemarituzumab FORTITUDE-102 Phase 3 data readout is anticipated in H2 2025/H1 2026.
• A randomized, double-blind pharmacokinetic similarity study of ABP 206 (nivolumab biosimilar) compared with OPDIVO is anticipated to have data readout in H2 2025.

Key Dates

Recommendation

Amgen delivered exceptional Q2 2025 results, significantly surpassing prior year performance in both revenue and EPS. The company's core product portfolio demonstrated robust volume growth, with 15 products achieving double-digit sales increases. Crucially, the pipeline is advancing with highly promising data, particularly for MariTide (GLP-1/GIPR) and IMDELLTRA (oncology), which have the potential to be significant future revenue drivers. The positive Phase 3 results for Bemarituzumab and Breakthrough Therapy Designation for LUMAKRAS further de-risk the pipeline. While biosimilar competition for Prolia and XGEVA is noted, the overall strength of the portfolio, strategic R&D investments, and confident 2025 guidance suggest sustained growth and strong long-term value creation. The 6% dividend increase also signals management's confidence.

Keywords

Amgen, AMGN, Biotechnology, Pharmaceuticals, Biologics, Oncology, Cardiovascular, Inflammation, Rare Disease, Biosimilars, GLP-1, MariTide, Earnings, Financial Results, SEC Filing, Q2 2025, Revenue, EPS, Pipeline, Clinical Trials, FDA, Drug Development, Weight Loss, Small Cell Lung Cancer, Gastric Cancer